Trial Profile
Effects of dose escalation on the safety and efficacy of Cabozantinib in patients with advanced/metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2018
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 14 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium